Article: Nicotinamide Riboside and Nicotinamide Mononucleotide Prevent Oxidative Stress in Blood Vessel Cells From COVID-19 Patients: Preclinical Findings

PrevNext
Cardiovascular Health COVID/Long-COVID Immune Health Preclinical

Nicotinamide Riboside and Nicotinamide Mononucleotide Prevent Oxidative Stress in Blood Vessel Cells From COVID-19 Patients: Preclinical Findings

Synopsis

COVID-19 is associated with vascular endothelial dysfunction, but mechanisms remain unclear. This study exposed human aortic endothelial cells (HAECs) to plasma from hospitalized COVID-19 patients and controls to assess effects on nitric oxide (NO) bioavailability, reactive oxygen species (ROS), and NAD+ levels. HAECs treated with COVID-19 plasma showed 27% reduced acetylcholine-stimulated NO production, 54% increased ROS, and 30% lower NAD+ concentrations, independent of age or sex. Co-treatment with NAD+ precursors nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN) restored NO production and reduced oxidative stress to control levels. These findings suggest that circulating factors in COVID-19 impair endothelial function via NAD+ depletion, and NAD+ precursor supplementation may offer therapeutic protection against vascular complications of COVID-19.

Journal

Nitric Oxide

Share

Read more

Glaucoma

Nicotinamide Riboside Protects Retinal Nerve Cells in Glaucoma: Preclinical Findings

SynopsisGlaucoma causes progressive retinal ganglion cell (RGC) degeneration and vision loss, often associated with elevated intraocular pressure (IOP). This study tested whether oral administratio...

Read more
Cellular Health

Nicotinamide Riboside Protects Against Ionizing Radiation-Induced Aging: Preclinical Findings

Synopsis Radiation therapy effectively kills cancer cells but can also damage healthy tissues, leading to premature aging and long-term side effects in survivors. In this study, researchers used a...

Read more